Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesDetection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients
European Journal of Haematology, 08/25/09
Kleber M et al. – The findings demonstrate that RI is frequent in MM, best detected via eGFR determination and an important prognostic factor. eGFR in combination with beta2–MG allows definitive risk stratification with largely differing survival in MM.
Related Articles
Hyperlipidemic myeloma: review of 53 cases
Annals of Hematology, 11/25/09
Relevance Score: 70%
Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry
Acta Haematologica, 11/04/09
Relevance Score: 69%
Characteristics of Orbital Multiple Myeloma: A Case Report and Literature Review
Survey of Ophthalmology, 10/23/09
Relevance Score: 69%
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 69%
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
Annals of Hematology, 11/25/09
Relevance Score: 68%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
British Journal of Haematology, 12/12/09
Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells
European Journal of Haematology, 12/11/09
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
Blood, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor